SNVIA

SNVIA is a clinical-stage biotechnology company dedicated to developing innovative therapies for blinding ocular diseases, with a primary focus on retinal disorders. The company's lead program, SNV-001, is a small molecule inhibitor designed to provide a long-acting, non-invasive or less frequent treatment option for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema. Founded by a team of experienced ophthalmology industry veterans, SNVIA leverages its deep expertise in drug development and ocular delivery to address significant unmet needs in the eye care market. The company aims to improve patient outcomes by reducing the treatment burden associated with current standard-of-care intravitreal injections. Through its focused pipeline, SNVIA is positioned to transform the management of chronic retinal conditions.